



22 september 2020







For numbered affiliations see end of the article.

Correspondence to:

L Wynants laure.wynants@ maastrichtuniversity.nl (ORCID 0000-0002-3037-122X)

Additional material is published online only. To view please visit the journal online.

Cita this as: RMI2020-360-m1329

Prediction models for diagnosis and prognosis of covid-19 infection: systematic review and critical appraisal


Laure Wynants, ^{1,2} Ben Van Calster, ^{2,3} Marc M J Bonten, ^{4,5} Gary S Collins, ^{6,7} Thomas P A Debray, ^{4,8} Maarten De Vos, ^{2,9} Maria C Haller, ^{10,11} Georg Heinze, ¹⁰ Karel G M Moons, ^{4,8} Richard D Riley, ¹² Ewoud Schuit, ^{4,8} Luc J M Smits, ¹ Kym I E Snell, ¹² Ewout W Steyerberg, ³ Christine Wallisch, ^{10,13,14} Maarten van Smeden ⁴

To review and critically appraise published and preprint reports of prediction models for diagnosing coronavirus disease 2019 (covid-19) in patients with suspected infection, for prognosis of patients with covid-19, and for detecting people in the general population at risk of being admitted to hospital for covid-19 pneumonia.

Original aim and set-up: not an LSR

- Prognosis and diagnosis -> not intervention studies review (and no MA)
- Not set-up as a living review -> set-up as a single rapid review

MARCH 2020




LSRs: now and in the future M.vanSmeden@umcutrecht.nl | Twitter: @MaartenvSmeden

Succes factors rapid review

- Highly experienced team: 14 prediction modeling experts
- Collaboration with the Cochrane Prognosis Methods Group
- Sense of high urgency (lockdown just started in NL)
 - **Dedicated time** of coordinators (LW, MVS)
- Experience with reporting (TRIPOD) and risk-of-bias tools (PROBAST)
 - Template data extraction form available

But... fast moving field

MARCH 2020



LSRs: now and in the future M.vanSmeden@umcutrecht.nl | Twitter: @MaartenvSmeden

BMJ editor comment


"We would like to take you up on your offer to update the review, as we realise this is a fast-moving area. We also wonder whether we might explore the possibility of periodic updates to this work, in other words to proceed with this as a "living" systematic review."

18 day sprint -> endurance race

currently working on our 3rd update

Published: April 7

Published: June 1







RESEARCH




Check for updates

Drug treatments for covid-19: living systematic review and network meta-analysis

So far:

- 359 citations (Google scholar)
- ~150k access on BMJ.com
- Picked-up by (some) media
- No end-of-update date





LSRs: now and in the future



, London, UK

Correspondence to: E Loder eloder@bmj.com

Cite this as: *BMJ* 2020;370:m2925 http://dx.doi.org/10.1136/bmj.m2925

Published: 31 July 2020

Livir

We wi

Helen

In mar of evid has fur and pr high q Systen way to a partiproduce behind Living allowing peer re relevan The concept of living systematic reviews is gathering momentum. The Cochrane Collaboration and *Annals* of Internal Medicine are also testing this format. 5 6 There are no broadly accepted criteria for when a living systematic review should be preferred to a traditional review, although guidance might be developed based on existing consensus about when to update traditional reviews. Reasons include methodological developments, changing clinical scenarios, and new information. Nor is there consensus about when is it time to stop one review and start work on a new one. Nonetheless, we will consider living systematic reviews in dynamic research areas, and we are willing to learn as we go.

thority urnals. he case e same

l ocesses cations


require rom


ng for

vs ar

ws are

Reasons for continuing the living review





Continuing flow of new articles coming out every day (>68k COVID articles)

Reasons for continuing the living review

Coo	rdin	ation	team
-----	------	-------	------

Laure Wynants (Maastricht)

Maarten van Smeden (Utrecht)

Carl Moons

Ben Van Calster (Leuven)

Information specialist

René Spijker (Utrecht)

Advisors

Marc Bonten (Utrecht)

Maarten De Vos (Leuven)

Liesbet Henckaerts

Experienced and dedicated team

Reviewers

Thomas Debray (Utrecht)

Valentijn de Jong

Ewoud Schuit

Hans Reitsma

Toshi Takada

Lotty Hooft

Anneke Damen

Constanza Navarro

Florien van Royen

Pauline Heus

Luc Smits (Maastricht)

Sander van Kuijk

Bas van Bussel

lwan van der Horst

Ewout Steyerberg (Leiden)

Anna Lohmann

Kim Luijken

Georg Heinze (Vienna)

Maria Haller

Christine Wallisch

Michael Kammer

Nina Kreuzberger (Cologne)

Nicole Skoetz

Darren Dahly (Cork)

Robert Wolff (York)

loana Tzoulaki (London)

Gary Collins (Oxford)

Jie Ma

Paula Dhiman

Richard Riley (Keele)

Kym Snell

Matthew Sperrin (Manchester)

Jamie Sergeant

Glen Martin

Jack Wilkinson

Chunhu Shi

Jan Verbakel (Leuven)

David McLernon (Aberdeen)

Michael Harhay (Philadelphia)

Reasons for continuing the living review

- No "saturation" yet: 145 models all evaluated at high risk of bias
- Important source of up-to-date information for ongoing prediction model validation projects (covid-precise IPD-MA consortium)




LSRs: now and in the future M.vanSmeden@umcutrecht.nl | Twitter: @MaartenvSmeden

"Living" with a living systematic review

- Lack of traditional academic/financial incentives
 - No "new publication reward" after first paper is published
 - No funding
 - Relies heavily on intrinsic motivation of reviewers



- Updates remain a large time investment
 - Re-evaluating the total evidence
 - Updating tables an figures, rewriting large pieces of text
 - Currently considering changing methods of presentation (30 vs 200 studies)



Other challenges

- Commitment to a project without end date
- How to deal with a dynamic pool of reviewers/contributors and authorship?
- How to handle 40 authors that want to comment on the updated paper?
- Editorial process

LSR when there is not a pandemic?

• For many research topics: keeping evidence synthesis up-to-date with a (dynamic) team of experts

But we will have to think carefully about:

- incentives for reviewers without pandemic urgency
- Agreed upon scheduled periodic updates and setting an end date
- Dynamic pool of reviewers

Also, make living reviews more doable

REPORTING GUIDELINES!

In our LSR we found very often:

- Inadequate description of the study populations
- Unclear intended use (and timing) of the models
- Model performance measures inadequately assessed/reported

Points to discuss

- How do we change the incentive system for LSR reviewers/contributors/journals?
- LSR: risks giving too much power to a small group of individuals?
- In slower pacing research fields: what is the incremental value of LSRs?